Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析

◆英語タイトル:Oasmia Pharmaceutical AB (OASM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14842
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes apealea (paclical), currently at registration and approval stage, for treating ovarian and metastatic breast cancer; doxophos for treating all doxorubicin indications; and preclinical stage products such as docecal (docetaxel), OAS-19 and KB9520. Its pipeline for animal health includes paccal vet (paklitaxel) and doxophos vet (doxorubicin), currently under phase 2 stage, intended for the treatment of mastocytoma and lymphoma, respectively. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB Key Recent Developments

Mar 01,2019: Oasmia Pharmaceutical: Interim report for the period May 2018 – January 2019
Nov 30,2018: Oasmia Pharmaceutical announce Interim report for the period May – October 2018
Nov 22,2018: Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Sep 25,2018: Annual General Meeting of Oasmia Pharmaceutical held on 25 September 2018

This comprehensive SWOT profile of Oasmia Pharmaceutical AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Oasmia Pharmaceutical AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Oasmia Pharmaceutical AB – Key Information
Oasmia Pharmaceutical AB – Overview
Oasmia Pharmaceutical AB – Key Employees
Oasmia Pharmaceutical AB – Key Employee Biographies
Oasmia Pharmaceutical AB – Key Operational Heads
Oasmia Pharmaceutical AB – Major Products and Services
Oasmia Pharmaceutical AB – History
Oasmia Pharmaceutical AB – Company Statement
Oasmia Pharmaceutical AB – Locations And Subsidiaries
Oasmia Pharmaceutical AB – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Oasmia Pharmaceutical AB – Business Description
Oasmia Pharmaceutical AB – Corporate Strategy
Oasmia Pharmaceutical AB – SWOT Analysis
SWOT Analysis – Overview
Oasmia Pharmaceutical AB – Strengths
Oasmia Pharmaceutical AB – Weaknesses
Oasmia Pharmaceutical AB – Opportunities
Oasmia Pharmaceutical AB – Threats
Oasmia Pharmaceutical AB – Key Competitors

Section 3 – Company Financial Performance Charts

Oasmia Pharmaceutical AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Oasmia Pharmaceutical AB, Key Information
Oasmia Pharmaceutical AB, Key Ratios
Oasmia Pharmaceutical AB, Share Data
Oasmia Pharmaceutical AB, Major Products and Services
Oasmia Pharmaceutical AB, History
Oasmia Pharmaceutical AB, Key Employees
Oasmia Pharmaceutical AB, Key Employee Biographies
Oasmia Pharmaceutical AB, Key Operational Heads
Oasmia Pharmaceutical AB, Other Locations
Oasmia Pharmaceutical AB, Subsidiaries
Oasmia Pharmaceutical AB, Key Manufacturing facilities
Oasmia Pharmaceutical AB, Key Competitors
Oasmia Pharmaceutical AB, SWOT Analysis
Oasmia Pharmaceutical AB, Ratios based on current share price
Oasmia Pharmaceutical AB, Annual Ratios
Oasmia Pharmaceutical AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Oasmia Pharmaceutical AB, Performance Chart
Oasmia Pharmaceutical AB, Ratio Charts

★海外企業調査レポート[Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EnviroMission Limited:電力:M&Aディール及び事業提携情報
    Summary EnviroMission Limited (EnviroMission) is a renewable energy company. It develops solar tower technology (STT). The company owns the license to STT across the world (excluding in China). EnviroMission’s STT uses solar radiation to heat air beneath a translucent canopy to create a solar therma …
  • TiGenix NV (TIG):企業の財務・戦略的SWOT分析
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • Oxford Performance Materials Inc-医療機器分野:企業M&A・提携分析
    Summary Oxford Performance Materials Inc (OPMI), a subsidiary of Arkema Inc is a chemical company that manufactures thermoplastic polymers. The company’s products include proprietary polyether ketone ketone formulations, additives, complex assemblies, biomedical raw materials, biomedical parts, robo …
  • Femasys Inc:医療機器:M&Aディール及び事業提携情報
    Summary Femasys Inc (Femasys) is a medical device company that develops and manufactures medical device solutions for women’s healthcare. The company offers non-surgical female sterilization devices, and devices for the diagnosis of infertility, and cervical cancer diagnosis. Its products include fe …
  • Olympia Vodice d.d.:企業の戦略・SWOT・財務情報
    Olympia Vodice d.d. - Strategy, SWOT and Corporate Finance Report Summary Olympia Vodice d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Marathon Oil Corporation:企業の戦略・SWOT・財務情報
    Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NSK Ltd.:企業の戦略・SWOT・財務情報
    NSK Ltd. - Strategy, SWOT and Corporate Finance Report Summary NSK Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Nigerian National Petroleum Corporation:企業の戦略的SWOT分析
    Nigerian National Petroleum Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Acacia Mining Plc:企業の戦略・SWOT・財務情報
    Acacia Mining Plc - Strategy, SWOT and Corporate Finance Report Summary Acacia Mining Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Viterra Inc.:企業の戦略・SWOT・財務分析
    Viterra Inc. - Strategy, SWOT and Corporate Finance Report Summary Viterra Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Tokyo Gas Co Ltd (9531)-エネルギー分野:企業M&A・提携分析
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • Bureau Veritas SA (BVI)-エネルギー分野:企業M&A・提携分析
    Summary Bureau Veritas SA (Bureau Veritas) is a testing, inspection and certification service provider that offers varied services such as asset management, certification, classification, consulting, inspection and audits, testing and analysis, and training. The company serves aeronautics, agricultu …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Lophius Biosciences GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Rocky Mountain Chocolate Factory, Inc.:企業の戦略・SWOT・財務分析
    Rocky Mountain Chocolate Factory, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rocky Mountain Chocolate Factory, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Carborundum Universal Ltd:企業の戦略・SWOT・財務情報
    Carborundum Universal Ltd - Strategy, SWOT and Corporate Finance Report Summary Carborundum Universal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Genome Institute of Singapore-医療機器分野:企業M&A・提携分析
    Summary Genome Institute of Singapore (GIS) is a research institute that provides various research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It handles the latest in technology and comprises early ca …
  • Publicis Groupe SA (PUB):企業の財務・戦略的SWOT分析
    Publicis Groupe SA (PUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nutricia GmbH:企業の戦略的SWOT分析
    Nutricia GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Yamana Gold Inc.:企業のM&A・事業提携・投資動向
    Yamana Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Yamana Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆